SCHEMBL2372446

SCHEMBL2372446

CCN(CC)C(=O)c1cc(Br)c(F)cc1Oc1ccc(Cl)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.36
KCNQ2 O43526 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SCN9A Q15858 3/20 0.36
KCNE1 P15382 1/20 0.35
KCNQ1 P51787 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
MAPT P10636 2/20 0.35
LPAR1 Q92633 1/20 0.34
LPAR5 Q9H1C0 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
PDE4B Q07343 1/20 0.34
LMNA P02545 2/20 0.34
GRM4 Q14833 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ACACB O00763 1/20 0.34
HPGD P15428 1/20 0.33
NMT2 O60551 1/20 0.33
NMT1 P30419 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370543 0.84 KCNQ3 (0.42) KCNQ3KCNQ2SCN9AKCNE1KCNQ1
SCHEMBL2370957 0.84 USP2 (0.42) ALDH1A1SCN9AL3MBTL1MAPTPDE4B
SCHEMBL2371072 0.81 LMNA (0.36) KCNQ3KCNQ2ALDH1A1L3MBTL1MAPT
SCHEMBL29693843 0.76 ALDH1A1 (0.60) ALDH1A1MAPTLMNATDP1HPGD
SCHEMBL1998955 0.68 ALDH1A1 (0.42) ALDH1A1SCN9AL3MBTL1MAPTLMNA
SCHEMBL570986 0.68 USP2 (0.45) ALDH1A1SCN9AL3MBTL1MAPTPDE4B
SCHEMBL1956720 0.67 FFAR4 (0.47) KCNQ3KCNQ2ALDH1A1KCNE1KCNQ1
SCHEMBL2370338 0.66 LMNA (0.43) KCNQ3KCNQ2KCNE1KCNQ1L3MBTL1
SCHEMBL991484 0.65 GRM5 (0.59) ALDH1A1L3MBTL1MAPTLMNAHPGD
SCHEMBL2370930 0.65 NAPRT (0.38) KCNQ3KCNQ2SCN9AKCNE1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP KCNQ3 1600/4885KCNQ2 1599/4885ALDH1A1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.